pharmaphorum
NOVEMBER 2, 2021
In 2019, there were 57 bsAb candidates in clinical trials, against both haematological and solid tumours. They eliminate the need to extract T cells for manipulation, expanding the accessibility of immuno-oncology to patients and clinical areas currently unmet by cell-based therapies, such as CAR T-cell treatments.
Drug Discovery World
JULY 22, 2022
For example, in randomised clinical trials of patients with non-small cell lung cancer (NSCLC), pembrolizumab has been shown to be effective in slowing down disease progression and improving survival rates 1. demonstrated the ability to model clinical responses to ACT in autologous HIS mice 4. Jespersen et al.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Discovery World
FEBRUARY 15, 2023
Genetically modified T cells stimulated with IL2 are now administered as cell therapy for multiple cancer cell types with beneficial results 3,4. Over 250 clinical trials are currently in progress, and novel immuno-oncological treatments are already proving to be successful. This continues to be the standard of care.
Drug Discovery World
JANUARY 23, 2023
Increasing interest in CRISPR-Cas gene editing systems over recent years has delivered innovative developments in precision genome engineering technologies, holding enormous potential for applications across the healthcare sector. These cells present a highly scalable platform, capable of manufacturing advanced cellular therapeutics.
Drug Discovery World
MAY 10, 2023
This stage is more highly regulated and consists of both preclinical testing and clinical trials. Dr Megan MacBride and Dr Caroline Horizny Mitchell , Taconic, examine recent changes to animal testing in drug design. Drug discovery and development is an arduous process that can cost upwards of $2.6 billion and take over 10 years.
Expert insights. Personalized for you.
52 
Let's personalize your content